Hjem › Ægstockræft › Ohio
Ægstockræft kliniske forsøg i Ohio
70 studier for Ægstockræft søger deltagere på steder i Ohio.
Byer i Ohio
- Columbus39 studier
- Cleveland30 studier
- Cincinnati19 studier
- Toledo12 studier
- Dayton9 studier
- Akron6 studier
- Parma4 studier
- Athens3 studier
- Marion3 studier
- Mansfield3 studier
- Mentor3 studier
Officiel studietekst (engelsk)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- OhioHealth O'Bleness Hospital, Athens
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- og 39 flere
RekruttererFase 2
Alle aldre · Alle køn · Opdateret 2. okt. 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06465069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Cleveland Clinic - Oncology Department, Cleveland
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06760819A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- University of Cincinnati Medical Center. /ID# 278925, Cincinnati
- University Hospitals Cleveland Medical Center /ID# 279601, Cleveland
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 1. okt. 2026 · NCT07024784Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
- Research Site, Cleveland
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 1. okt. 2026 · NCT07851025A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 06, Maumee
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07814248A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0147 - Trihealth Cancer Institute - Harold and Eugen, Cincinnati
- Site 0243 - Mark H Zangmeister Cancer Center, Columbus
- Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 29. sep. 2026 · NCT05128825A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
- Cleveland Clinic - Cleveland /ID# 276133, Cleveland
- Cleveland Clinic - Cleveland /ID# 278273, Cleveland
- og 3 flere
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 29. sep. 2026 · NCT06890338Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Cleveland Clinic, Cleveland
RekruttererObservationsstudie
Alder 18 og opefter · Kvinder · Opdateret 29. sep. 2026 · NCT05051722Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05867251DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
RekruttererObservationsstudie
Alder 18 til 130 · Alle køn · Opdateret 25. sep. 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT04981119Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- The Ohio State University Wexner Medical Center, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Kvinder · Opdateret 25. sep. 2026 · NCT03564340A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- The Ohio State University Wexner Medical Center, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Kvinder · Opdateret 24. sep. 2026 · NCT04590326Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Cincinnati
- Research Site, Columbus
RekruttererFase 2
Alder 18 til 130 · Alle køn · Opdateret 23. sep. 2026 · NCT05489211A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 22. sep. 2026 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Miami Valley Hospital South, Centerville
- University of Cincinnati Medical Center, Cincinnati
- Oncology Hematology Care Inc, Cincinnati
- og 7 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07213804A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- UH Cleveland Medical Center, Cleveland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07109726A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- University of Cincinnati Medical Center ( Site 0042), Cincinnati
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 17. sep. 2026 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Oncology Hematology Care, Inc, Cincinnati
- The Mark H Zangmeister Cancer Center Ohio, Columbus
- The Ohio State University Wexner Medical Center Division of Gynecologic Oncology, Hilliard
RekruttererFase 2
Alder 18 til 99 · Kvinder · Opdateret 15. sep. 2026 · NCT07023627Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Cleveland Clinic Foundation, Cleveland
- Ohio Health Research Institute, Columbus
- Miami Valley Hospital South, Dayton
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 15. sep. 2026 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Christ Hospital, Cincinnati
- Ohio State University, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT06303505Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- Cleveland Clinic, Cleveland
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 14. sep. 2026 · NCT04575935Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- The Ohio State University Comprehensive Cancer Center, Hilliard
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 14. sep. 2026 · NCT06787612ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT05059444Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Miami Valley Hospital South, Centerville
- Zangmeister Cancer Center, Columbus
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 9. sep. 2026 · NCT07225270A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The Ohio State University (OSU) Wexner Medical Center, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT06400472A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- University of Cincinnati Medical Center ( Site 0090), Cincinnati
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 3. sep. 2026 · NCT06824467The Vanguard Study: Testing a New Way to Screen for Cancer
- Louis Stokes Cleveland VA Medical Center, Cleveland
RekruttererFrivillige med god helbredstilstand velkomne
Alder 45 til 75 · Alle køn · Opdateret 2. sep. 2026 · NCT06995898Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Cleveland Clinic, Cleveland
- OhioHealth Research Institute, Columbus
- Kettering Health, Kettering
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 26. aug. 2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- The Ohio State University, Columbus
RekruttererFase 1
Alder 15 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererFase 1/2
12 Months – 30 Years · Alle køn · Opdateret 25. aug. 2026 · NCT04851119A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Cleveland Clinic Taussig Cancer Institute, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 21. aug. 2026 · NCT06774963Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Columbus
RekruttererFase 1/2
Alder 18 til 130 · Alle køn · Opdateret 21. aug. 2026 · NCT05797168Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT07001748A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Maumee
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT07182149A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Ohio State University Wexner Medical Center, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT07470853Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererTidlig fase 1
Alder 18 og opefter · Kvinder · Opdateret 17. aug. 2026 · NCT07144826Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- The Ohio State University, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 13. aug. 2026 · NCT05985655Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.